The global immunoassay market size was values at USD 28.29 billion in 2025 and is anticipated to grow from USD 29.52 billion in 2026 to USD 42.43 billion by 2034, growing at a CAGR of 4.64% during the forecast period 2026-2034. North America dominated the immunoassay market with a market share of 39.5% in 2025.
An immunoassay is a laboratory test that uses the specific binding between an antigen and an antibody to detect or measure a substance in a sample such as blood, urine, or saliva.
Download a Free Sample To learn more about this report,
Growing Use of Chemiluminescence Immunoassays over Traditional Elisa Methods
The global immunoassay market is witnessing a significant shift toward chemiluminescence immunoassays (CLIA) due to their higher sensitivity, precision, and faster turnaround times compared to traditional ELISA methods. CLIA is increasingly adopted in hospitals, laboratories, and point-of-care settings to support early disease detection and monitoring.
Such innovations highlight the rising preference for CLIA systems globally.
Growing Adoption of Point-of-Care Immunoassays
The growing adoption of point-of-care immunoassays is significantly boosting the global market, as these tests provide rapid, accurate, and convenient disease detection at decentralized healthcare facilities. Their increasing use in managing infectious diseases, chronic conditions, and emergency care is enhancing diagnostic efficiency and patient outcomes.
Such innovations strengthen accessibility, enabling timely treatment decisions and driving global immunoassay market growth.
Rising Prevalence of Chronic and Infectious Diseases Worldwide
The global market is strongly driven by the rising prevalence of chronic and infectious diseases, creating a growing demand for reliable diagnostic tools. Chronic conditions and infectious outbreaks continue to burden healthcare systems, necessitating advanced testing solutions for early detection and effective management.
Immunoassays, with their high sensitivity and specificity, play a crucial role in monitoring disease progression, guiding treatment, and improving patient outcomes globally.
Growing Demand for Early and Accurate Disease Diagnosis
The global immunoassay market is significantly driven by the rising need for early and precise disease detection to improve treatment outcomes. Immunoassays provide high sensitivity and specificity, making them indispensable in diagnosing chronic and infectious diseases.
High Cost of Advanced Systems and Reagents
The high cost of advanced immunoassay systems and reagents remains a significant restraint to market growth, particularly in resource-limited settings. These systems require prominent investment in both equipment and consumables, making affordability a challenge for smaller laboratories and healthcare facilities.
Additionally, recurring expenses for specialized reagents and maintenance further increase the financial burden, restricting wider adoption in developing regions.
Expanding Immunoassay Applications in Veterinary Diagnostics
The veterinary diagnostics sector is emerging as a significant growth avenue for immunoassays, driven by rising awareness of animal health and the increasing prevalence of zoonotic and infectious diseases among pets and livestock. Immunoassays offer rapid, accurate, and cost-effective diagnostic solutions for veterinary clinics and research laboratories.
Such advancements highlight a widening opportunity to diversify applications and capture growth in emerging diagnostic segments.
According to the World Health Organization (WHO), nearly 47% of the global population has limited access to essential diagnostics, with affordability and infrastructure remaining major barriers, particularly in low- and middle-income countries.
Rising prices of monoclonal antibodies, enzymes, and other biological raw materials, coupled with inflationary pressures, have further increased manufacturing costs for diagnostic companies. These factors slow the adoption of advanced immunoassay platforms and reduce testing accessibility in cost-sensitive healthcare markets.
Request Customizationto receive a tailored report.
Reagents & Kits Dominated the Market with 61.80% Share in 2025
Reagents & kits accounted for the largest share of the global immunoassay market at 61.80% in 2025, driven by their recurring use in diagnostic testing, increasing test volumes, and continuous demand across clinical laboratories and hospitals.
Rapid Tests are Projected to Register the Fastest Growth at a CAGR of 8.65%
The rapid tests segment is expected to expand at the highest CAGR of 8.65% during 2026–2034, supported by growing demand for point-of-care diagnostics, faster turnaround times, and increasing adoption in infectious disease screening.
Blood Emerged as the Leading Specimen Segment with 72.6% Market Share in 2025
The blood specimen segment held the largest market share of 72.6% in 2025, owing to its widespread use in immunoassay-based testing for infectious diseases, cancer biomarkers, hormones, and chronic disease diagnostics.
Oncology is Expected to be the Fastest-Growing Application with a CAGR of 9.15%
The oncology segment is anticipated to witness the fastest growth, registering a CAGR of 9.15% during 2026–2034, fueled by increasing cancer incidence, rising demand for biomarker-based diagnostics, and advancements in personalized medicine.
Speak to an Analystto discuss market opportunities.
North America dominated the global immunoassay market with a 39.5% market share, valued at USD 11.17 billion in 2025. The region benefits from advanced healthcare infrastructure, high diagnostic testing volumes, favorable reimbursement policies, and strong adoption of automated immunoassay systems. Growing prevalence of chronic diseases, cancer, and infectious diseases continues to support market expansion.
The United States accounted for an estimated USD 9.60 billion of the market in 2025, making it the largest contributor in North America. Growth is driven by increasing adoption of precision diagnostics, extensive clinical laboratory networks, and continuous investments in molecular and immunodiagnostic technologies. The presence of major industry players such as Abbott, Thermo Fisher Scientific, Danaher, and Bio-Rad further strengthens the country's market position.
Canada generated an estimated USD 0.78 billion in 2025. Rising government healthcare expenditure, increasing chronic disease screening, and growing investments in hospital laboratory modernization are driving demand for advanced immunoassay testing across the country.
Europe accounted for 27.2% of the global immunoassay market, reaching USD 7.69 billion in 2025. The market is supported by strong public healthcare systems, expanding cancer screening initiatives, increasing laboratory automation, and the implementation of the EU In Vitro Diagnostic Regulation (IVDR), which is encouraging the adoption of high-quality diagnostic solutions.
The United Kingdom represented an estimated USD 1.15 billion in 2025. The country's market is driven by NHS investments in early disease diagnosis, increasing adoption of point-of-care testing, and growing demand for biomarker-based diagnostics to improve patient outcomes.
Germany led the European market with an estimated value of USD 2.08 billion in 2025. The country's strong diagnostics manufacturing base, high healthcare expenditure, and continuous investments in laboratory automation and precision medicine continue to support market growth.
Asia Pacific accounted for 22.4% of the global market, valued at USD 6.34 billion in 2025, and is projected to register the fastest CAGR of 9.35% during the forecast period. Rising healthcare expenditure, expanding diagnostic infrastructure, growing awareness of preventive healthcare, and increasing chronic disease prevalence are accelerating market growth across the region.
Japan generated an estimated USD 1.33 billion in 2025. The country's aging population, high incidence of chronic diseases, and rapid adoption of advanced immunodiagnostic technologies continue to fuel demand for immunoassay-based testing across hospitals and research laboratories.
China accounted for an estimated USD 2.54 billion in 2025, making it the largest market in Asia Pacific. Government healthcare reforms, expanding hospital infrastructure, increasing domestic diagnostic manufacturing, and rising investments in precision medicine are driving strong market growth.
The Middle East & Africa represented 4.8% of the global immunoassay market, totaling USD 1.36 billion in 2025. Increasing investments in healthcare infrastructure, rising demand for early disease detection, and expanding laboratory capabilities are supporting regional market growth.
The United Arab Emirates (UAE) accounted for an estimated USD 0.28 billion in 2025. The market is driven by government investments in healthcare modernization, increasing adoption of automated laboratory technologies, and the country's emergence as a regional hub for specialized diagnostic services.
Africa is witnessing steady growth in the immunoassay market, supported by expanding access to diagnostic services, increasing infectious disease surveillance programs, and international investments in laboratory capacity. Countries such as South Africa, Kenya, and Nigeria are strengthening diagnostic infrastructure to improve testing capabilities for HIV, tuberculosis, malaria, and non-communicable diseases, creating long-term growth opportunities for immunoassay manufacturers.
Unlock Regional Insightsto access country-level data, & regional trends.
The global immunoassay market is moderately fragmented in nature due to numerous global and regional players competing across diverse immunoassay applications. The top players in the industry are Abbott Laboratories, F. Hoffmann-La Roche Ltd., Siemens Healthineers, Danaher Corporation, Thermo Fisher Scientific Inc., bioMérieux SA, and others.
The industry participants are inclined towards product expansion to meet growing demand, diversify offerings, enhance competitive advantage, adopt advanced technologies, and cater to emerging applications in diagnostics, personalized medicine, and point-of-care testing.
Labcorp: An Emerging Market Player
Labcorp, a leading global life sciences company, offers extensive diagnostic solutions, including immunoassay-based testing. With advanced laboratories, strong R&D, and strategic collaborations, Labcorp plays a vital role in disease diagnosis, drug development, and personalized healthcare services worldwide.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a Healthcare Lead with over 7 years of industry experience, specializing in Healthcare IT. She provides comprehensive market insights on digital health, electronic medical records, telehealth, and healthcare analytics. Debashree’s research supports organizations in adopting technology-driven healthcare solutions, improving patient care, and achieving operational efficiency in a rapidly transforming healthcare ecosystem.
We are featured on:
sales@straitsresearch.com